Feb 12, 2026 · Caplyta is used to treat adults with schizophrenia, depression associated with bipolar I or bipolar II disorder (manic depression), or along with antidepressant medicines to treat major …

Nov 6, 2025 · Caplyta is an oral capsule that is used to treat mental health conditions, including schizophrenia, depression, and bipolar disorder. Common side effects include dizziness, drowsiness, …

CAPLYTA ® (lumateperone) is a prescription medicine used in adults along with an antidepressant to treat major depressive disorder (MDD); to treat depressive episodes associated with bipolar I or …

Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families.

The safety of CAPLYTA has been evaluated in placebo-controlled clinical trials that included 3575 adult patients with schizophrenia, bipolar depression, or major depressive disorder, exposed to...

May 6, 2026 · A summary of the clinical data regarding the long-term use of CAPLYTA® (lumateperone).

May 15, 2026 · Caplyta (Lumateperone) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.

Jul 9, 2026 · Following administration of CAPLYTA 42 mg, the highest D 2 RO level in the dorsal striatum was observed at 1 hour, with a mean±SD occupancy of 39%±12% (n=6).

CAPLYTA is an FDA-approved treatment option in adults with schizophrenia, bipolar I and II depression, and as an adjunctive therapy for major depressive disorder (MDD).

Nov 6, 2025 · Lumateperone (Caplyta) is used to treat adults with schizophrenia, depression associated with bipolar I or bipolar II disorder (manic depression), or along with antidepressant medicines to …